Countagen AB

Countagen AB is a Swedish biotechnology company that specializes in genomic safety and gene editing analysis tools. The company developed the LockSeq platform, a targeted next-generation sequencing (NGS) library preparation system designed to provide high-fidelity genome editing characterization. By utilizing ligation-locked chemistry to circularize target molecules before amplification, the technology minimizes target dropout, reduces amplification bias, and provides sequence-level resolution to detect rare variants. Additionally, the company offers GeneAbacus, a PCR-free, DNA-based digital quantification assay that allows researchers to validate gene editing efficiency and specificity in-house within hours using standard laboratory equipment.

These tools are designed to solve critical bottlenecks in the cell and gene therapy (CGT) pipeline, enabling academic, pharmaceutical, and biotech researchers to accelerate development while ensuring the safety and precision of their gene-editing workflows. By providing standardized, high-resolution validation, Countagen aims to support the discovery and development of innovative therapies. The company was founded in 2020 by a team of molecular biologists and entrepreneurs from Karolinska Institutet and SciLifeLab, and it maintains its headquarters within the Karolinska Institutet biotech ecosystem in Solna, Sweden.